IL17A and myeloid sarcoma: Serotonin not only acts directly on Th1 cells to reduce their production of IFN-γ in MS patients, but also reduces the production of IL-17 and IFN-γ from Th17 in PBMCs isolated from MS patients (Sacramento et al. 2018).